Strand Therapeutics and BeiGene enter into agreement to develop solid tumor immuno-oncology therapeutics based on Strand’s next-generation, multi-functional mRNA technology

 PRESS RELEASE   01/2021

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--Jan. 11, 2021-- Strand Therapeutics, a privately held developer of next-generation, programmable mRNA therapeutics for cancer and other diseases, and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) today announced that they have entered into an option and license agreement aimed at developing and commercializing Strand’s innovative, multi-functional mRNA treatments for solid tumors. BeiGene has secured an option to an exclusive license to develop and commercialize in Asia (excluding Japan), Australia, and New Zealand up to two immuno-oncology programs using Strand’s intratumoral or systemic delivery mechanism, which is designed to deliver a tumor microenvironment-modifying mRNA directly to the tumor site.


Rate this resource